Advertisement

Virally Induced Cancers

  • Ravinder S. Gogia
  • Shawnbir Gogia
  • Sarah T. Arron
Chapter

Abstract

Immunosuppressed patients are at particular risk for skin cancers caused by, or associated with, viral infection. This chapter reviews three viral-associated skin cancers: human herpesvirus-8-associated Kaposi’s sarcoma, Merkel cell polyomavirus-associated Merkel cell carcinoma, and HPV-associated cutaneous squamous cell carcinoma.

Keywords

Virus Cancer Squamous cell carcinoma Merkel cell carcinoma Kaposi’s sarcoma 

Abbreviations

AIDS

Acquired immunodeficiency syndrome

AJCC

American Joint Committee on Cancer

AK

Actinic keratosis

BCC

Basal cell carcinoma

CK20

Cytokeratin 20

CLL

Chronic lymphocytic leukemia

cSCC

Cutaneous squamous cell carcinoma

EGFR

Epidermal growth factor receptor

EV

Epidermodysplasia verruciformis

HAART

Highly active antiretroviral treatment

HHV-8

Human herpesvirus-8

HIV

Human immunodeficiency virus

HPV

Human papilloma virus

IRIS

Immune reconstitution inflammatory syndrome

KC

Keratinocyte carcinoma

KS

Kaposi’s sarcoma

KSHV

Kaposi’s sarcoma-associated herpesvirus

LANA

Latency-associated nuclear antigen

LTAg

Large T antigen

MCC

Merkel cell carcinoma

MCD

Multicentric Castleman’s Disease

MCPyV

Merkel cell polyomavirus

NSE

Neuron-specific enolase

PEL

Primary effusion lymphoma

Rb

Retinoblastoma

SEER

Surveillance, epidemiology, and end results program

SLNB

Sentinel lymph node biopsy

SOTR

Solid organ transplant recipients

TTF-1

Thyroid transcription factor-1

UVR

Ultraviolet radiation

VEGF

Vascular endothelial growth factor

vGPCR

Viral G protein-coupled receptor

vIL-6

Viral IL-6

References

  1. 1.
    Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006;118:3030–44.  https://doi.org/10.1002/ijc.21731.CrossRefPubMedGoogle Scholar
  2. 2.
    Arron ST, Jennings L, Nindl I, et al. Viral oncogenesis and its role in nonmelanoma skin cancer. Br J Dermatol. 2011;164:1201–13.  https://doi.org/10.1111/j.1365-2133.2011.10322.x.CrossRefPubMedGoogle Scholar
  3. 3.
    Arron ST, Ruby JG, Dybbro E, et al. Transcriptome sequencing demonstrates that human papillomavirus is not active in cutaneous squamous cell carcinoma. J Investig Dermatol. 2011;131:1745–53.  https://doi.org/10.1038/jid.2011.91.CrossRefPubMedCentralPubMedGoogle Scholar
  4. 4.
    Alam M, Ratner D. Cutaneous squamous-cell carcinoma. N Engl J Med. 2001;344:975–83.  https://doi.org/10.1056/NEJM200103293441306.CrossRefPubMedGoogle Scholar
  5. 5.
    Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. 2012;166:1069–80.  https://doi.org/10.1111/j.1365-2133.2012.10830.x.CrossRefPubMedGoogle Scholar
  6. 6.
    Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med. 2003;348:1681–91.  https://doi.org/10.1056/NEJMra022137.CrossRefPubMedGoogle Scholar
  7. 7.
    Cubie HA. Diseases associated with human papillomavirus infection. Virology. 2013;445:21–34.  https://doi.org/10.1016/j.virol.2013.06.007.CrossRefPubMedGoogle Scholar
  8. 8.
    Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet. 2007;370:890–907.  https://doi.org/10.1016/S0140-6736(07)61416-0.CrossRefPubMedGoogle Scholar
  9. 9.
    Kempf W, Mertz KD, Hofbauer GFL, Tinguely M. Skin cancer in organ transplant recipients. Pathobiology. 2013;80:302–9.  https://doi.org/10.1159/000350757.CrossRefPubMedGoogle Scholar
  10. 10.
    Connolly K, Manders P, Earls P, Epstein RJ. Papillomavirus-associated squamous skin cancers following transplant immunosuppression: one Notch closer to control. Cancer Treat Rev. 2014;40:205–14.  https://doi.org/10.1016/j.ctrv.2013.08.005.CrossRefPubMedGoogle Scholar
  11. 11.
    Alter M, Satzger I, Mattern A, et al. Treatment of advanced cutaneous squamous cell carcinomas with epidermal growth factor receptor inhibitors. Dermatology (Basel). 2013;227:289–94.  https://doi.org/10.1159/000355181.CrossRefGoogle Scholar
  12. 12.
    Diepgen TL, Mahler V. The epidemiology of skin cancer. Br J Dermatol. 2002;146(Suppl 61):1–6.CrossRefPubMedGoogle Scholar
  13. 13.
    Schwartz RA. Verrucous carcinoma of the skin and mucosa. J Am Dermatol. 1995;32:1–21; quiz 22–4.CrossRefGoogle Scholar
  14. 14.
    Vandeweyer E, Sales F, Deraemaecker R. Cutaneous verrucous carcinoma. Br J Plast Surg. 2001;54:168–70.  https://doi.org/10.1054/bjps.2000.3440.CrossRefPubMedGoogle Scholar
  15. 15.
    Sterling JC. Human papillomaviruses and skin cancer. J Clin Virol. 2005;32:67–71.  https://doi.org/10.1016/j.jcv.2004.11.018.CrossRefGoogle Scholar
  16. 16.
    Bhat P, Mattarollo SR, Gosmann C, et al. Regulation of immune responses to HPV infection and during HPV-directed immunotherapy. Immunol Rev. 2011;239:85–98.  https://doi.org/10.1111/j.1600-065X.2010.00966.x.CrossRefPubMedGoogle Scholar
  17. 17.
    Euvrard S, Morelon E, Rostaing L, et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med. 2012;367:329–39.  https://doi.org/10.1056/NEJMoa1204166.CrossRefPubMedGoogle Scholar
  18. 18.
    Nguyen P, Vin-Christian K, Ming ME, Berger T. Aggressive squamous cell carcinomas in persons infected with the human immunodeficiency virus. Arch Dermatol. 2002;138:758–63.CrossRefPubMedGoogle Scholar
  19. 19.
    Crum-Cianflone N, Hullsiek KH, Satter E, et al. Cutaneous malignancies among HIV-infected persons. Arch Intern Med. 2009;169:1130–8.  https://doi.org/10.1001/archinternmed.2009.104.CrossRefPubMedCentralPubMedGoogle Scholar
  20. 20.
    Crum-Cianflone N, Hullsiek KH, Marconi V, et al. Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS. 2009;23:41–50.  https://doi.org/10.1097/QAD.0b013e328317cc2d.CrossRefPubMedCentralPubMedGoogle Scholar
  21. 21.
    Arnold AW, Hofbauer GFL. Human papillomavirus and squamous cell cancer of the skin--epidermodysplasia verruciformis-associated human papillomavirus revisited. Curr Probl Dermatol. 2012;43:49–56.  https://doi.org/10.1159/000335151.CrossRefPubMedGoogle Scholar
  22. 22.
    Zampetti A, Giurdanella F, Manco S, et al. Acquired epidermodysplasia verruciformis: a comprehensive review and a proposal for treatment. Dermatol Surg. 2013;39:974–80.  https://doi.org/10.1111/dsu.12135.CrossRefPubMedGoogle Scholar
  23. 23.
    Muñoz N, Castellsagué X, de González AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine. 2006;24:S1–S10.  https://doi.org/10.1016/j.vaccine.2006.05.115.CrossRefGoogle Scholar
  24. 24.
    Jackson S, Harwood C, Thomas M. Role of Bak in UV-induced apoptosis in skin cancer and abrogation by HPV E6 proteins. Genes Dev. 2000;14(23):3065–73.  https://doi.org/10.1101/gad.CrossRefPubMedCentralPubMedGoogle Scholar
  25. 25.
    Iftner T, Elbel M, Schopp B, et al. Interference of papillomavirus E6 protein with single-strand break repair by interaction with XRCC1. EMBO J. 2002;21(17)):4741–8.CrossRefPubMedCentralPubMedGoogle Scholar
  26. 26.
    Weissenborn SJ, Nindl I, Purdie K, et al. Human papillomavirus-DNA loads in actinic keratoses exceed those in non-melanoma skin cancers. J Invest Dermatol. 2005;125:93–7.  https://doi.org/10.1111/j.0022-202X.2005.23733.x.CrossRefPubMedGoogle Scholar
  27. 27.
    Bavinck JNB, Plasmeijer EI, Feltkamp MCW. β-Papillomavirus infection and skin cancer. J Investig Dermatol. 2008;128:1355–8.  https://doi.org/10.1038/jid.2008.123.CrossRefGoogle Scholar
  28. 28.
    Farasat S, Yu SS, Neel VA, et al. A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: creation and rationale for inclusion of tumor (T) characteristics. J Am Acad Dermatol. 2011;64:1051–9.  https://doi.org/10.1016/j.jaad.2010.08.033.CrossRefPubMedCentralPubMedGoogle Scholar
  29. 29.
    Karia PS, Jambusaria-Pahlajani A, Harrington DP, et al. Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women’s Hospital tumor staging for cutaneous squamous cell carcinoma. J Clin Oncol. 2014;32:327–34.  https://doi.org/10.1200/JCO.2012.48.5326.CrossRefPubMedGoogle Scholar
  30. 30.
    Jambusaria-Pahlajani A, Kanetsky PA, Karia PS, et al. Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system. JAMA Dermatol. 2013;149:402–10.  https://doi.org/10.1001/jamadermatol.2013.2456.CrossRefPubMedGoogle Scholar
  31. 31.
    Miller SJ. Staging cutaneous squamous cell carcinoma. JAMA Dermatol. 2013;149:472–4.  https://doi.org/10.1001/jamadermatol.2013.2385.CrossRefPubMedGoogle Scholar
  32. 32.
    Schmitt AR, Brewer JD, Bordeaux JS, Baum CL. Staging for cutaneous squamous cell carcinoma as a predictor of sentinel lymph node biopsy results: meta-analysis of American joint committee on cancer criteria and a proposed alternative system. JAMA Dermatol. 2013;150:19.  https://doi.org/10.1001/jamadermatol.2013.6675.CrossRefGoogle Scholar
  33. 33.
    Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567–78.  https://doi.org/10.1056/NEJMoa053422.CrossRefPubMedGoogle Scholar
  34. 34.
    Leard LE, Cho BK, Jones KD, et al. Fatal diffuse alveolar damage in two lung transplant patients treated with cetuximab. J Heart Lung Transplant. 2007;26:1340–4.  https://doi.org/10.1016/j.healun.2007.09.019.CrossRefPubMedGoogle Scholar
  35. 35.
    Hasan S. The role of postoperative radiation and chemoradiation in Merkel cell carcinoma: a systematic review of the literature. Front Oncol. 2013;3:276.  https://doi.org/10.3389/fonc.2013.00276/abstract.CrossRefPubMedCentralPubMedGoogle Scholar
  36. 36.
    Eng TY, Boersma MG, Fuller CD, et al. A comprehensive review of the treatment of Merkel cell carcinoma. Am J Clin Oncol. 2007;30:624–36.  https://doi.org/10.1097/COC.0b013e318142c882.CrossRefPubMedGoogle Scholar
  37. 37.
    Kuwamoto S. Recent advances in the biology of Merkel cell carcinoma. Hum Pathol. 2011;42:1063–77.  https://doi.org/10.1016/j.humpath.2011.01.020.CrossRefPubMedGoogle Scholar
  38. 38.
    Senchenkov A, Moran SL. Merkel cell carcinoma. Plast Reconstr Surg. 2013;131:771e–8e.  https://doi.org/10.1097/PRS.0b013e3182865cf3.CrossRefPubMedGoogle Scholar
  39. 39.
    Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science. 2008;319:1096–100.  https://doi.org/10.1126/science.1152586.CrossRefPubMedCentralPubMedGoogle Scholar
  40. 40.
    Shuda M, Feng H, Kwun HJ, et al. T antigen mutations are a human tumor-specific signature for Merkel cell polyomavirus. Proc Natl Acad Sci. 2008;105:16272–7.  https://doi.org/10.1073/pnas.0806526105.CrossRefPubMedCentralPubMedGoogle Scholar
  41. 41.
    Albores-Saavedra J, Batich K, Chable-Montero F, et al. Merkel cell carcinoma demographics, morphology, and survival based on 3870 cases: a population based study. J Cutan Pathol. 2010;37:20–7.  https://doi.org/10.1111/j.1600-0560.2009.01370.x.CrossRefPubMedGoogle Scholar
  42. 42.
    Zhan FQ, Packianathan VS, Zeitouni NC. Merkel cell carcinoma: a review of current advances. J Natl Compr Cancer Netw. 2009;7:333–9.CrossRefGoogle Scholar
  43. 43.
    Heath M, Jaimes N, Lemos B, et al. Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features. J Am Acad Dermatol. 2008;58:375–81.  https://doi.org/10.1016/j.jaad.2007.11.020.CrossRefPubMedCentralPubMedGoogle Scholar
  44. 44.
    Pectasides D. Merkel cell cancer of the skin. Ann Oncol. 2006;17:1489–95.  https://doi.org/10.1093/annonc/mdl050.CrossRefPubMedGoogle Scholar
  45. 45.
    Campillo R, Gil-Carcedo E, Alonso D, et al. Primary cutaneous neuroendocrine carcinoma, Merkel cell carcinoma. Case series 1991–2012. Acta Otorrinolaringol. 2013;64:396–402.  https://doi.org/10.1016/j.otoeng.2013.11.005.CrossRefGoogle Scholar
  46. 46.
    Buell JF, Trofe J, Hanaway MJ, et al. Immunosuppression and Merkel cell cancer. Transplant Proc. 2002;34:1780–1.CrossRefPubMedGoogle Scholar
  47. 47.
    Pulitzer MP, Amin BD, Busam KJ. Merkel cell carcinoma: review. Adv Anat Pathol. 2009;16:135–44.  https://doi.org/10.1097/PAP.0b013e3181a12f5a.CrossRefPubMedGoogle Scholar
  48. 48.
    Schrama D, Ugurel S, Becker JC. Merkel cell carcinoma. Curr Opin Oncol. 2012;24:141–9.  https://doi.org/10.1097/CCO.0b013e32834fc9fe.CrossRefPubMedGoogle Scholar
  49. 49.
    Becker JC. Merkel cell carcinoma. Ann Oncol. 2010;21:vii81–5.  https://doi.org/10.1093/annonc/mdq366.CrossRefPubMedGoogle Scholar
  50. 50.
    McCalmont TH. Connect the dots. J Cutan Pathol. 2013;40:921–3.  https://doi.org/10.1111/cup.12238.CrossRefPubMedGoogle Scholar
  51. 51.
    Lin Z, McDermott A, Shao L, et al. Chronic mTOR activation promotes cell survival in Merkel cell carcinoma. Cancer Lett. 2014;344:272–81.  https://doi.org/10.1016/j.canlet.2013.11.005.CrossRefPubMedGoogle Scholar
  52. 52.
    Engels EA, Frisch M, Goedert JJ, et al. Merkel cell carcinoma and HIV infection. Lancet. 2002;359:497–8.  https://doi.org/10.1016/S0140-6736(02)07668-7.CrossRefPubMedGoogle Scholar
  53. 53.
    Sihto H, Kukko H, Koljonen V, et al. Clinical factors associated with Merkel cell polyomavirus infection in Merkel cell carcinoma. J Natl Cancer Inst. 2009;101:938–45.  https://doi.org/10.1093/jnci/djp139.CrossRefPubMedGoogle Scholar
  54. 54.
    Triozzi P, Fernandez A. The role of the immune response in Merkel cell carcinoma. Cancers. 2013;5:234–54.  https://doi.org/10.3390/cancers5010234.CrossRefPubMedCentralPubMedGoogle Scholar
  55. 55.
    Stetsenko GY, Malekirad J, Paulson KG, et al. p63 expression in Merkel cell carcinoma predicts poorer survival yet may have limited clinical utility. Am J Clin Pathol. 2013;140:838–44.  https://doi.org/10.1309/AJCPE4PK6CTBNQJY.CrossRefPubMedCentralPubMedGoogle Scholar
  56. 56.
    Bichakjian CK, Olencki T, Alam M, Andersen JS. Merkel cell carcinoma, version 1.2014. J Natl Compr Canc Netw. 2014;12(3):410–24.CrossRefPubMedGoogle Scholar
  57. 57.
    Miller NJ, Bhatia S, Parvathaneni U, et al. Emerging and mechanism-based therapies for recurrent or metastatic Merkel cell carcinoma. Curr Treat Options in Oncol. 2013;14:249–63.  https://doi.org/10.1007/s11864-013-0225-9.CrossRefGoogle Scholar
  58. 58.
    Ruocco E, Ruocco V, Tornesello ML, et al. Kaposi’s sarcoma: etiology and pathogenesis, inducing factors, causal associations, and treatments: facts and controversies. Clin Dermatol. 2013;31:413–22.  https://doi.org/10.1016/j.clindermatol.2013.01.008.CrossRefPubMedGoogle Scholar
  59. 59.
    Schwartz RA, Micali G, Nasca MR, Scuderi L. Kaposi sarcoma: a continuing conundrum. J Am Acad Dermatol. 2008;59:179–206; quiz 207–8.  https://doi.org/10.1016/j.jaad.2008.05.001.CrossRefPubMedGoogle Scholar
  60. 60.
    Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science. 1994;266:1865–9.CrossRefPubMedGoogle Scholar
  61. 61.
    Buonaguro FM, Tornesello ML, Beth Giraldo E, et al. Herpesvirus-like DNA sequences detected in endemic, classic, iatrogenic and epidemic Kaposi's sarcoma (KS) biopsies. Int J Cancer. 1996;65:25–8.  https://doi.org/10.1002/(SICI)1097-0215(19960103)65:1<25::AID-IJC5>3.0.CO;2-3.CrossRefPubMedGoogle Scholar
  62. 62.
    Moore PS, Chang Y. Kaposi’s sarcoma (KS), KS-associated herpesvirus, and the criteria for causality in the age of molecular biology. Am J Epidemiol. 1998;147:217–21.CrossRefPubMedGoogle Scholar
  63. 63.
    Moore PS, Chang Y. Kaposi's sarcoma-associated herpesvirus immunoevasion and tumorigenesis: two sides of the same coin? Annu Rev Microbiol. 2003;57:609–39.  https://doi.org/10.1146/annurev.micro.57.030502.090824.CrossRefPubMedCentralPubMedGoogle Scholar
  64. 64.
    Ma T, Jham BC, Hu J, et al. Viral G protein-coupled receptor up-regulates Angiopoietin-like 4 promoting angiogenesis and vascular permeability in Kaposi's sarcoma. Proc Natl Acad Sci U S A. 2010;107:14363–8.  https://doi.org/10.1073/pnas.1001065107.CrossRefPubMedCentralPubMedGoogle Scholar
  65. 65.
    Sodhi A, Montaner S, Patel V, et al. The Kaposi’s sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha. Cancer Res. 2000;60(17):4873–80.PubMedGoogle Scholar
  66. 66.
    Montaner S, Sodhi A, Molinolo A, et al. Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi’s sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell. 2003;3(1):23–36.CrossRefPubMedGoogle Scholar
  67. 67.
    Moses AV, Jarvis MA, Raggo C, et al. Kaposi’s sarcoma-associated herpesvirus-induced upregulation of the c-kit proto-oncogene, as identified by gene expression profiling, is essential for the transformation of endothelial cells. J Virol. 2002;76(16):8383–99.  https://doi.org/10.1128/jvi.76.16.8383-8399.2002.CrossRefPubMedCentralPubMedGoogle Scholar
  68. 68.
    Sarid R, Klepfish A, Schattner A. Virology, pathogenetic mechanisms, and associated diseases of Kaposi sarcoma-associated herpesvirus (human herpesvirus 8). Mayo Clin Proc. 2002;77:941–9.  https://doi.org/10.4065/77.9.941.CrossRefPubMedGoogle Scholar
  69. 69.
    Godden-Kent D, Talbot SJ, Boshoff C, et al. The cyclin encoded by Kaposi’s sarcoma-associated herpesvirus stimulates cdk6 to phosphorylate the retinoblastoma protein and histone H1. J Virol. 1997;71:4193–8.PubMedCentralPubMedGoogle Scholar
  70. 70.
    Friborg J, Kong W, Hottiger MO, Nabel GJ. p53 inhibition by the LANA protein of KSHV protects against cell death. Nature. 1999;402:889–94.  https://doi.org/10.1038/47266.CrossRefPubMedGoogle Scholar
  71. 71.
    Eaton C, Dorer R, Aboulafia DM. Human Herpesvirus-8 infection associated with Kaposi sarcoma, multicentric Castleman’s disease, and plasmablastic microlymphoma in a man with AIDS: a case report with review of pathophysiologic processes. Pathol Res Int. 2011;2011:1–6.  https://doi.org/10.4061/2011/647518.CrossRefGoogle Scholar
  72. 72.
    Neipel F, Albrecht JC, Ensser A, et al. Human herpesvirus 8 encodes a homolog of interleukin-6. J Virol. 1997;71:839–42.PubMedCentralPubMedGoogle Scholar
  73. 73.
    Diehl S, Rincón M. The two faces of IL-6 on Th1/Th2 differentiation. Mol Immunol. 2002;39:531–6.CrossRefPubMedGoogle Scholar
  74. 74.
    Grayson W, Pantanowitz L. Histological forms of cutaneous Kaposi sarcoma. Diagn Pathol. 2008;3:31.  https://doi.org/10.1186/1746-1596-3-31.CrossRefPubMedCentralPubMedGoogle Scholar
  75. 75.
    Iscovich J, Boffetta P, Franceschi S, et al. Classic Kaposi sarcoma: epidemiology and risk factors. Cancer. 2000;88:500–17.CrossRefPubMedGoogle Scholar
  76. 76.
    Schneider E, Whitmore S, Glynn KM, Dominguez K. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years—United States, 2008. MMWR Recomm Rep. 2008;57(RR-10):1–12.PubMedGoogle Scholar
  77. 77.
    Eltom MA, Jemal A, Mbulaiteye SM, et al. Trends in Kaposi’s sarcoma and non-Hodgkin’s lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst. 2002;94:1204–10.CrossRefPubMedGoogle Scholar
  78. 78.
    Rubinstein PG, Aboulafia DM, Zloza A. Malignancies in HIV/AIDS: from epidemiology to therapeutic challenges. AIDS. 2014;28(4):453–65.  https://doi.org/10.1097/QAD.0000000000000071.CrossRefPubMedCentralPubMedGoogle Scholar
  79. 79.
    Mocroft A, Kirk O, Clumeck N, et al. The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003. Cancer. 2004;100:2644–54.  https://doi.org/10.1002/cncr.20309.CrossRefPubMedGoogle Scholar
  80. 80.
    Sasco AJ, Jaquet A, Boidin E, et al. The challenge of AIDS-related malignancies in sub-Saharan Africa. PLoS One. 2010;5:e8621.  https://doi.org/10.1371/journal.pone.0008621.CrossRefPubMedCentralPubMedGoogle Scholar
  81. 81.
    Bower M. Immune reconstitution inflammatory syndrome associated with Kaposi’s sarcoma. J Clin Oncol. 2005;23:5224–8.  https://doi.org/10.1200/JCO.2005.14.597.CrossRefPubMedGoogle Scholar
  82. 82.
    Lesnoni La Parola I, Masini C, Nanni G, et al. Kaposi’s sarcoma in renal-transplant recipients: experience at the Catholic University in Rome, 1988-1996. Dermatology (Basel). 1997;194:229–33.CrossRefGoogle Scholar
  83. 83.
    Boshoff C, Weiss RA. Epidemiology and pathogenesis of Kaposi’s sarcoma-associated herpesvirus. Philos Trans R Soc Lond Ser B Biol Sci. 2001;356:517–34.  https://doi.org/10.1098/rstb.2000.0778.CrossRefGoogle Scholar
  84. 84.
    Schwartz RA. Kaposi's sarcoma: An update. J Surg Oncol. 2004;87:146–51.  https://doi.org/10.1002/jso.20090.CrossRefPubMedGoogle Scholar
  85. 85.
    Radu O, Pantanowitz L. Kaposi sarcoma. Arch Pathol Lab Med. 2013;137:289–94.  https://doi.org/10.5858/arpa.2012-0101-RS.CrossRefPubMedGoogle Scholar
  86. 86.
    Sullivan RJ, Pantanowitz L, Casper C, et al. HIV/AIDS: epidemiology, pathophysiology, and treatment of Kaposi sarcoma–associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease. Clin Infect Dis. 2008;47:1209–15.  https://doi.org/10.1086/592298.CrossRefPubMedCentralPubMedGoogle Scholar
  87. 87.
    Soulier J, Grollet L, Oksenhendler E, et al. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood. 1995;86:1276–80.PubMedGoogle Scholar
  88. 88.
    Patel S, Xiao P. Primary effusion lymphoma. Arch Pathol Lab. 2013.  https://doi.org/10.5858/arpa.2012-0294-RS)
  89. 89.
    Antman K, Chang Y. Kaposi’s sarcoma. N Engl J Med. 2000;342:1027–38.  https://doi.org/10.1056/NEJM200004063421407.CrossRefPubMedGoogle Scholar
  90. 90.
    Ramdial PK, Chetty R, Singh B, et al. Lymphedematous HIV-associated Kaposi’s sarcoma. J Cutan Pathol. 2006;33:474–81.  https://doi.org/10.1111/j.1600-0560.2006.00352.x.CrossRefPubMedGoogle Scholar
  91. 91.
    Régnier-Rosencher E, Guillot B, Dupin N. Treatments for classic Kaposi sarcoma: a systematic review of the literature. J Am Acad Dermatol. 2013;68:313–31.  https://doi.org/10.1016/j.jaad.2012.04.018.CrossRefPubMedGoogle Scholar
  92. 92.
    Di Lorenzo G, Konstantinopoulos PA, Pantanowitz L, et al. Management of AIDS-related Kaposi’s sarcoma. Lancet Oncol. 2007;8:167–76.  https://doi.org/10.1016/S1470-2045(07)70036-0.CrossRefPubMedGoogle Scholar
  93. 93.
    Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi’s sarcoma in renal-transplant recipients. N Engl J Med. 2005;352:1317–23.  https://doi.org/10.1056/NEJMoa042831.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Ravinder S. Gogia
    • 1
  • Shawnbir Gogia
    • 2
  • Sarah T. Arron
    • 1
  1. 1.Department of DermatologyUniversity of California, San FranciscoSan FranciscoUSA
  2. 2.School of Medicine, University of California, San FranciscoSan FranciscoUSA

Personalised recommendations